PURPOSE: We determined the cancer control provided by nephron sparing surgery for renal cell carcinoma greater than 4 cm. MATERIALS AND METHODS: We performed a retrospective review of data on patients treated between 1980 and 2005. The case characteristics analyzed were patient age, surgical procedure, intraoperative parameters, complications, tumor size, Fuhrman grade, TNM stage, pathological data and outcome. Kaplan-Meier survival curves were generated. RESULTS: Median age of the 61 patients was 64 years (range 40 to 83). Mean +/- SD intraoperative blood loss was 622 ml +/- 691 (range 50 to 4,800) and mean operative time was 155.7 +/- 82 minutes (range 52 to 360). Mean creatinine preoperatively and immediately postoperatively was 1.16 and 1.25 mg/dl, respectively. Mean renal cell carcinoma size was 56.3 +/- 18 mm (range 41 to 100). Margin status was positive in 11 cases (18%). Median followup was 70.7 months. The 5 and 10-year cancer specific survival rate was 81% and 78%, respectively. The tumor-free survival rate was 92% at 5 years and 88% at 10 years. On univariate analysis tumor size more than 7 cm (p = 0.002), pathological stage (p = 0.001) and Fuhrman grade (p = 0.004) were associated with survival. On multivariate analysis only pathological stage and Fuhrman grade were significant (p <0.0001 and 0.007, respectively). CONCLUSIONS: Our results support the fact that nephron sparing surgery is a useful and acceptable approach to renal cell carcinoma greater than 4 cm. When technically possible, nephron sparing surgery provides acceptable long-term cancer specific survival rates. However, oncological safety is less evident in cases of renal cell carcinoma greater than 7 cm. To date in such cases nephron sparing surgery should only be considered for absolute indications.
PURPOSE: We determined the cancer control provided by nephron sparing surgery for renal cell carcinoma greater than 4 cm. MATERIALS AND METHODS: We performed a retrospective review of data on patients treated between 1980 and 2005. The case characteristics analyzed were patient age, surgical procedure, intraoperative parameters, complications, tumor size, Fuhrman grade, TNM stage, pathological data and outcome. Kaplan-Meier survival curves were generated. RESULTS: Median age of the 61 patients was 64 years (range 40 to 83). Mean +/- SD intraoperative blood loss was 622 ml +/- 691 (range 50 to 4,800) and mean operative time was 155.7 +/- 82 minutes (range 52 to 360). Mean creatinine preoperatively and immediately postoperatively was 1.16 and 1.25 mg/dl, respectively. Mean renal cell carcinoma size was 56.3 +/- 18 mm (range 41 to 100). Margin status was positive in 11 cases (18%). Median followup was 70.7 months. The 5 and 10-year cancer specific survival rate was 81% and 78%, respectively. The tumor-free survival rate was 92% at 5 years and 88% at 10 years. On univariate analysis tumor size more than 7 cm (p = 0.002), pathological stage (p = 0.001) and Fuhrman grade (p = 0.004) were associated with survival. On multivariate analysis only pathological stage and Fuhrman grade were significant (p <0.0001 and 0.007, respectively). CONCLUSIONS: Our results support the fact that nephron sparing surgery is a useful and acceptable approach to renal cell carcinoma greater than 4 cm. When technically possible, nephron sparing surgery provides acceptable long-term cancer specific survival rates. However, oncological safety is less evident in cases of renal cell carcinoma greater than 7 cm. To date in such cases nephron sparing surgery should only be considered for absolute indications.
Authors: Mas Jewett; A Finelli; C Kollmannsberger; L Wood; L Legere; J Basiuk; C Canil; D Heng; N Reaume; S Tanguay; M Atkins; G Bjarnason; J Dancey; M Evans; N Fleshner; M Haider; A Kapoor; R Uzzo; D Maskens; D Soulieres; G Yousef; N Basappa; N Bendali; P Black; N Blais; I Cagiannos; M Care; R Chow; H Chung; P Czaykowski; D Derosa; K Durrant; S Ellard; G Farquharson; C Filion-Brulotte; J Gingerich; L Godbout; R Grant; W Hamilton; W Kassouf; G Kurban; K Lane; Jb Lattouf; D Lau; M Leveridge; J McCarthy; R Moore; S North; P O'brien; E Pituskin; P Racine; R Rendon; A So; S Sridhar; K Stubbs; Z Su; L Taylor; T Udall; P Venner; W Vogel; S Yap; P Yau; M Cooper; N Giroux; D Miron; D Mosher; K Ross; J Willacy Journal: Can Urol Assoc J Date: 2012-02 Impact factor: 1.862
Authors: Matthias Waldert; Sandra Waalkes; Tobias Klatte; Markus A Kuczyk; Peter Weibl; Gerd Schüller; Axel S Merseburger; Mesut Remzi Journal: World J Urol Date: 2010-07-07 Impact factor: 4.226
Authors: Gopal N Gupta; James Peterson; Kailash N Thakore; Peter A Pinto; W Marston Linehan; Gennady Bratslavsky Journal: J Urol Date: 2010-05-15 Impact factor: 7.450
Authors: Jeremiah J Morrissey; Vincent M Mellnick; Jingqin Luo; Marilyn J Siegel; R Sherburne Figenshau; Sam Bhayani; Evan D Kharasch Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Ercan Malkoc; Daniel Ramirez; Onder Kara; Matthew J Maurice; Ryan J Nelson; Peter A Caputo; Jihad H Kaouk Journal: World J Urol Date: 2016-09-23 Impact factor: 4.226